Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
第一作者:
Dan,Stark
第一单位:
Leeds Institute of Molecular Medicine, University of Leeds, St James's Institute of Oncology, Leeds, UK. Electronic address: d.p.stark@leeds.ac.uk.
作者:
医学主题词
成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);卵巢肿瘤(Ovarian Neoplasms);生活质量(Quality of Life);治疗结果(Treatment Outcome)
DOI
10.1016/S1470-2045(12)70567-3
PMID
23333117
发布时间
2025-05-29
- 浏览17
The Lancet. Oncology
236-43页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



